Evidence map›Paper›PMID 20101529›Full record

ReviewMolecular neurobiology2010

Abnormal mitochondrial dynamics--a novel therapeutic target for Alzheimer's disease?

Bo Su, Xinglong Wang, David Bonda, Gorge Perry, Mark Smith, Xiongwei Zhu

Open access · greenAbstract readReview
In one paragraph

Review in Molecular neurobiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 81 citations in OpenAlex.

  1. Article
  2. Review
  3. Mitochondria in health, disease, and aging.Physiological reviews · 2023
    Review
  4. Article
  5. Mechanisms associated with the dysregulation of mitochondrial function due to lead exposure and possible implications on the development of Alzheimer's disease.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2022
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Bo SuDepartment of Pathology, Case Western Reserve University, 2103 Cornell Road, Cleveland, OH 44106, USA.
Xinglong Wang
David Bonda
Gorge Perry
Mark Smith
Xiongwei Zhu
Cornell University · USCase Western Reserve University · USThe University of Texas at San Antonio · US

Funding

Mitochondrial Fission and Fusion in Alzheimer DiseaseR01AG031852 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI ZHU, XIONGWEI · 2008 to 2012
$1.6M
NIA NIH HHS AG031852NIA NIH HHS R01 AG031852
6 · The paper itself

Abstract

Mitochondria are dynamic organelles that undergo continuous fission and fusion, which could affect all aspects of mitochondrial function. Mitochondrial dysfunction has been well documented in Alzheimer's disease (AD). In the past few years, emerging evidence indicates that an imbalance of mitochondrial dynamics is involved in the pathogenesis of AD. In this review, we discuss in detail the abnormal mitochondrial dynamics in AD and how such abnormal dynamics may impact mitochondrial and neuronal function and contribute to the course of disease. Based on this discussion, we propose that mitochondrial dynamics could be a potential therapeutic target for AD.

Indexed as

Alzheimer DiseaseAnimalsAntioxidantsApolipoprotein E4Clinical Trials as TopicHumansIndolesMitochondriaNeuronsPresenilinstau ProteinsAntioxidantsApolipoprotein E4IndoleslatrepirdinePresenilinstau Proteins

Identifiers

PMID20101529
PMCPMC3129743
OpenAlexW2089940631

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.